Biotech News

Purple Biotech's IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium

Purple Biotech (PPBT)Purple BiotechConference / presentation

Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of preclinical data on IM1240, the lead capped tri-specific antibody from its CAPTN-3 platform, in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18-20, 2026, in Barcelona, Spain.

Related news

Purple Biotech

Next-Generation Immuno-Oncology Platform Purple Biotech develops next-generation immunotherapies designed to increase antitumor activity while limiting toxicity. Its CAPTN-3 platform consists of masked trispecific antibodies that simultaneously target tumors and activate T cells and natural killer cells. IM1240 Trispecific...

Recent company news

Stock data

Close
1.53 USD
Market cap
2.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States